Gross Profit Trends Compared: Alnylam Pharmaceuticals, Inc. vs Grifols, S.A.

Biopharma Giants: Alnylam's Surge vs. Grifols' Stability

__timestampAlnylam Pharmaceuticals, Inc.Grifols, S.A.
Wednesday, January 1, 2014505610001699214000
Thursday, January 1, 2015410970001930998000
Friday, January 1, 2016471590001912291000
Sunday, January 1, 2017765450002152011000
Monday, January 1, 2018731060002049560000
Tuesday, January 1, 20191946880002341232000
Wednesday, January 1, 20204148010002255165000
Friday, January 1, 20217041430001962596000
Saturday, January 1, 20228686010002231530000
Sunday, January 1, 202315178860002322701000
Monday, January 1, 20241924873000
Loading chart...

Igniting the spark of knowledge

A Tale of Two Biopharma Giants: Alnylam vs. Grifols

In the ever-evolving landscape of biopharmaceuticals, Alnylam Pharmaceuticals, Inc. and Grifols, S.A. have carved distinct paths over the past decade. From 2014 to 2023, Alnylam's gross profit surged by an impressive 2,900%, reflecting its innovative strides in RNA interference therapeutics. Meanwhile, Grifols, a leader in plasma-derived medicines, maintained a steady growth trajectory, with gross profits increasing by approximately 37% over the same period.

Key Insights

  • Alnylam's Breakthroughs: Starting with a modest gross profit in 2014, Alnylam's financial growth mirrors its successful product launches and expanding market reach.
  • Grifols' Consistency: Despite a more modest growth rate, Grifols' consistent performance underscores its robust business model and market stability.

This comparison highlights the dynamic nature of the biopharma sector, where innovation and stability play pivotal roles in shaping financial outcomes.

Published by
U.S. Securities and Exchange Commission

Source link
sec.gov

Date published
17 Jan 2025